Sugi Predict

Sugi Predict / Targets / CLK2

CLK2

Dual specificity protein kinase CLK2 · P49760 · CLK2 on Sugi Atlas →

215,622 patent compounds predicted against CLK2, 159,151 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL23608 SCHEMBL23608 0.43 7/20
SCHEMBL81513 SCHEMBL81513 0.56 6/20
SCHEMBL81160 SCHEMBL81160 0.52 6/20
SCHEMBL24327 SCHEMBL24327 0.44 5/20
SCHEMBL82789 SCHEMBL82789 0.46 4/20
SCHEMBL72322 SCHEMBL72322 0.73 3/20
SCHEMBL72323 SCHEMBL72323 0.73 3/20
SCHEMBL73871 SCHEMBL73871 0.70 3/20
SCHEMBL73872 SCHEMBL73872 0.70 3/20
SCHEMBL82928 SCHEMBL82928 0.69 3/20
SCHEMBL84772 SCHEMBL84772 0.65 3/20
SCHEMBL72298 SCHEMBL72298 0.64 3/20
SCHEMBL72299 SCHEMBL72299 0.64 3/20
SCHEMBL74215 SCHEMBL74215 0.62 3/20
SCHEMBL74216 SCHEMBL74216 0.62 3/20
SCHEMBL84783 SCHEMBL84783 0.60 3/20
SCHEMBL68662 SCHEMBL68662 0.58 3/20
SCHEMBL98881 SCHEMBL98881 0.57 3/20
SCHEMBL84779 SCHEMBL84779 0.57 3/20
SCHEMBL82655 SCHEMBL82655 0.55 3/20

Clinical trials — most relevant to CLK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) PHASE1/PHASE2RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification PHASE2COMPLETED
Niraparib in Patients With Pancreatic Cancer PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia PHASE2ACTIVE_NOT_RECRUITING
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib PHASE2COMPLETED
Biological Effects of Quercetin in COPD Phase II PHASE2UNKNOWN
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors PHASE1RECRUITING
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers nanCOMPLETED
Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment nanENROLLING_BY_INVITATION
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Genomic Analysis of Families With a History of Discordant Cancers nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CLK2 binder may also engage these)

ProteinNameSimilarity
O35491 — 1.000 O35491 →
P22518 — 0.997 P22518 →
CLK4 Dual specificity protein kinase CLK4 0.995 landscape →
CLK1 Dual specificity protein kinase CLK1 0.993 landscape →
Q3SX21 — 0.993 Q3SX21 →
Q63117 — 0.993 Q63117 →
O35492 — 0.992 O35492 →
CLK3 Dual specificity protein kinase CLK3 0.989 landscape →
O35493 — 0.987 O35493 →
Q4WYR6 — 0.975 Q4WYR6 →
Q5BAE1 — 0.974 Q5BAE1 →
Q9LV37 — 0.974 Q9LV37 →
Q5SN53 — 0.974 Q5SN53 →
Q23357 — 0.973 Q23357 →
P51566 — 0.972 P51566 →
Q4FCZ5 — 0.972 Q4FCZ5 →
Q4I5U9 — 0.972 Q4I5U9 →
A2X0M1 — 0.972 A2X0M1 →
Q53N72 — 0.972 Q53N72 →
Q0E459 — 0.972 Q0E459 →
O35832 — 0.971 O35832 →
Q5VP69 — 0.971 Q5VP69 →
Q09437 — 0.970 Q09437 →
Q96VK3 — 0.970 Q96VK3 →
Q8W4J2 — 0.970 Q8W4J2 →
Q9LFT8 — 0.970 Q9LFT8 →
A1CL96 — 0.970 A1CL96 →
DCLK1 Serine/threonine-protein kinase DCLK1 0.970 landscape →
P46551 — 0.970 P46551 →
Q75KK8 — 0.970 Q75KK8 →